Letters to the Editor

Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona
Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona
Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona
Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona
Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme
Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme
Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid
Advanced and Cell Therapy Services. Banc de Sang i Teixits, Barcelona
Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine; Faculty of Biology, University of Freiburg, Freiburg
HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary
Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona
Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Genetics Unit, Hospital Universitario y Politécnico La Fe, Valencia
Department of Immunology, University Hospital of Gran Canaria Dr. Negrin, Canarian Health System, Las Palmas de Gran Canaria, Spain; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria
Servei d'Hematologia Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, IIB Sant Pau/Josep Carreras Leukaemia Research Institute (IJC), Barcelona
Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona
Pediatric Hematology and Oncology Division, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona
Pediatric Department, Universidad Autonoma de Madrid, Madrid, Spain; Hospital La Paz Institute for Health Research, Madrid, Spain; Pediatric Hemato-Oncology Department, University Hospital La Paz, Madrid
Servicio de Hematología Hospital Clínico Universitario de Salamanca, salamanca, Spain; Instituto Biosanitario de Salamanca (IBSAL). Salamanca
Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Servicio de Hematología, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Immunology Department, Dr. Balmis General University Hospital; Institute for Health and Biomedical Research (ISABIAL), Alicante
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Area de Hemato-Oncología, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain; Servicio de Hematologia, CCUN, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Josep Carreras Leukaemia Research Institute. Department of Biomedicine. School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terapias Avanzadas (TERAV) - Instituto de Salud Carlos III, Madrid, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
Servei d’Hematologia, Vall d’Hebron Hospital Universitari; Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO); Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona
Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain; Epigenetics in Inflammatory and Metabolic Diseases Laboratory, Health Science Center (HSC), East China Normal University (ECNU), Shanghai
HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University. Budapest, Hungary
Centro de Investigación Biomédica en Red de Oncología (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Programa de Investigación en Cáncer, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Josep Carreras Leukaemia Research Institute (IJC), Barcelona
Department of Hematology and Oncology, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid
Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN
Regenerative Medicine Program, Bellvitge Institute for Biomedical Research (IDIBELL) and Program for Clinical Translation of Regenerative Medicine in Catalonia (P-CMRC), Barcelona, Spain; Fondazione Pisana Per la Scienza ONLUS (FPS), San Giuliano Terme, Italy; Department of Pathology and Experimental Therapeutics, Faculty of Medicine and Health Sciences, Barcelona University, Barcelona
Vol. 108 No. 9 (2023): September, 2023 https://doi.org/10.3324/haematol.2022.282305